Evidence-Based Nutritional Supplementation in Polycystic Ovary Syndrome: A Comprehensive Review of Clinical Outcomes, Mechanisms, and Recommendations
Authors
-
Nusly Andres-Montenegro
Facultad de ciencias, (Universidad Nacional Autónoma de Honduras/ Tegucigalpa / Honduras)
https://orcid.org/0009-0006-9445-9403
-
Sidnee Molina-Gutierrez
Facultad de ciencias, (Universidad Nacional Autónoma de Honduras/ Tegucigalpa / Honduras)
https://orcid.org/0009-0006-3424-6633
-
Olinda Núñez-Murillo
Instituto de Investigaciones en Microbiología, (Universidad Nacional Autónoma de Honduras/ Tegucigalpa/Honduras)
https://orcid.org/0000-0002-1921-7838
DOI:
https://doi.org/10.70099/BJ/2025.02.02.13Keywords:
Polycystic Ovary Syndrome, Nutritional Supplements, Inositol, Omega-3 Fatty Acids, Coenzyme Q10, Vitamin D, Selenium, Insulin Resistance, Clinical Trials, Evidence-Based Review, Endocrine MetabolismAbstract
Polycystic Ovary Syndrome (PCOS) is a prevalent and multifactorial endocrine-metabolic disorder among women of reproductive age. Recent research indicates that nutritional supplementation may play a valuable adjunctive role in PCOS management, particularly in addressing metabolic, hormonal, and inflammatory disturbances. This review synthesizes evidence from randomized controlled trials and meta-analyses published up to 2024, evaluating the efficacy and safety of commonly used supplements such as myo-inositol, vitamin D, omega-3 fatty acids, selenium, and coenzyme Q10. The analysis demonstrates that several supplements can improve insulin sensitivity, lipid profiles, hormonal balance, and oxidative stress markers in women with PCOS. Mechanistic insights suggest these effects are mediated through the modulation of metabolic and inflammatory pathways, including AMPK, NF-κB, PPAR-γ, and VDR. Nevertheless, the heterogeneity of study designs, sample sizes, and a paucity of long-term safety data highlight the need for standardized protocols and further high-quality trials. Overall, nutritional supplements offer a promising strategy for personalized PCOS management, especially for women with insulin resistance or those seeking alternatives to conventional pharmacotherapy. Continued research into optimal dosing, duration, and co-supplementation effects will be essential to refine clinical recommendations and maximize patient outcomes. This is the most comprehensive synthesis, combining clinical outcomes with mechanistic insights across 13 key nutritional supplements in PCOS management.References
1. Concha CF, Recabarren SE, Pérez BF. Epigenética del síndrome de ovario poliquístico. Rev Med Chil. 2017;145(7):907-15. doi:10.4067/s0034-98872017000700907.
2. Heidari H, Hajhashemy Z, Saneei P. A meta-analysis of effects of vitamin E supplementation alone and in combination with omega-3 or magnesium on polycystic ovary syndrome. Sci Rep. 2022;12:19927. doi:10.1038/s41598-022-24467-0.
3. Ortiz AE, Luque M, Escobar HF. Polycystic ovary syndrome in adult women. Med Clin (Barc). 2019;152(10):450-7. doi:10.1016/j.medcli.2018.11.019.
4. Kiani AK, Donato K, Dhuli K, Stuppia L, Bertelli M. Dietary supplements for polycystic ovary syndrome. J Prev Med Hyg. 2022;63(2 Suppl 3):E206-E213. doi:10.15167/2421-4248/jpmh2022.63.2S3.2762.
5. Shivyari FT, Pakniat H, Nooshabadi MR, Rostami S, Haghighian HK, Shiri-Shahsavari MR. Examining the oleoylethanolamide supplement effects on glycemic status, oxidative stress, inflammation, and anti-müllerian hormone in polycystic ovary syndrome. J Ovarian Res. 2024;17(1):111. doi:10.1186/s13048-024-01432-1.
6. Luo J, Li T, Yuan J. Effectiveness of vitamin D supplementation on lipid profile in polycystic ovary syndrome women: a meta-analysis of randomized controlled trials. Ann Palliat Med. 2021;10(1):114-29. doi:10.21037/apm-20-2492.
7. Wen X, Wang L, Li F, Yu X. Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial. J Ovarian Res. 2024;17(1):147. doi:10.1186/s13048-024-01473-6.
8. Jin B, Qian L, Fu X, Zhu J, Shu J. Influence of vitamin D supplementation on lipid levels in polycystic ovary syndrome patients: a meta-analysis of randomized controlled trials. J Int Med Res. 2020;48(6):300060520935313. doi:10.1177/0300060520935313.
9. Samimi M, Zarezade Mehrizi M, Foroozanfard F, Akbari H, Jamilian M, Ahmadi S, et al. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2017;86(4):560-6. doi:10.1111/cen.13288.
10. Izadi A, Ebrahimi S, Shirazi S, Taghizadeh S, Parizad M, Farzadi L, et al. Hormonal and Metabolic Effects of Coenzyme Q10 and/or Vitamin E in Patients With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019;104(2):319-27. doi:10.1210/jc.2018-01221.
11. Heshmati J, Moini A, Sepidarkish M, Morvaridzadeh M, Salehi M, Palmowski A, et al. Effects of curcumin supplementation on blood glucose, insulin resistance and androgens in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Phytomedicine. 2021;80:153395. doi:10.1016/j.phymed.2020.153395.
12. Sohaei S, Amani R, Tarrahi MJ, Ghasemi-Tehrani H. The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial. Complement Ther Med. 2019;47:102201. doi:10.1016/j.ctim.2019.102201.
13. Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014;102(2):460-8.e3. doi:10.1016/j.fertnstert.2014.04.046.
14. Menichini D, Facchinetti F. Effects of vitamin D supplementation in women with polycystic ovary syndrome: a review. Gynecol Endocrinol. 2020;36(1):1-5. doi:10.1080/09513590.2019.1625881.
15. Maktabi M, Chamani M, Asemi Z. The Effects of Vitamin D Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Horm Metab Res. 2017;49(6):493-8. doi:10.1055/s-0043-107242.
16. Akbari M, Ostadmohammadi V, Lankarani KB, Tabrizi R, Kolahdooz F, Heydari ST, et al. The Effects of Vitamin D Supplementation on Biomarkers of Inflammation and Oxidative Stress Among Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2018;50(4):271-9. doi:10.1055/s-0044-101355.
17. Alesi S, Ee C, Moran LJ, Rao V, Mousa A. Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome. Adv Nutr. 2022;13(4):1243-66. doi:10.1093/advances/nmab141.
18. Tarkesh F, Namavar Jahromi B, Hejazi N, Tabatabaee H. Beneficial health effects of Menaquinone-7 on body composition, glycemic indices, lipid profile, and endocrine markers in polycystic ovary syndrome patients. Food Sci Nutr. 2020;8(10):5612-21. doi:10.1002/fsn3.1837.
19. Ziaei S, Hasani M, Malekahmadi M, Daneshzad E, Kadkhodazadeh K, Heshmati J. Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials. J Ovarian Res. 2024;17(1):138. doi:10.1186/s13048-024-01450-z.
20. Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21(1):10. doi:10.1186/s12958-023-01055-z.
21. Fitz V, Graca S, Mahalingaiah S, Liu J, Lai L, Butt A, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630-55. doi:10.1210/clinem/dgad762.
22. Shokrpour M, Foroozanfard F, Afshar Ebrahimi F, Vahedpoor Z, Aghadavod E, Ghaderi A, et al. Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. Gynecol Endocrinol. 2019;35(5):406-11. doi:10.1080/09513590.2018.1540570.
23. Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014;30(6):438-43. doi:10.3109/09513590.2014.897321.
24. Jamilian M, Bahmani F, Siavashani MA, Mazloomi M, Asemi Z, Esmaillzadeh A. The Effects of Chromium Supplementation on Endocrine Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2016;172(1):72-8. doi:10.1007/s12011-015-0570-6.
25. Jamilian M, Asemi Z. Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Nutr Metab. 2015;67(1):42-8. doi:10.1159/000438465.
26. Rashidi BH, Mohammad Hosseinzadeh F, Alipoor E, Asghari S, Yekaninejad MS, Hosseinzadeh-Attar MJ. Effects of Selenium Supplementation on Asymmetric Dimethylarginine and Cardiometabolic Risk Factors in Patients with Polycystic Ovary Syndrome. Biol Trace Elem Res. 2020;196(2):430-7. doi:10.1007/s12011-019-01954-6.
27. Razavi M, Jamilian M, Kashan ZF, Heidar Z, Mohseni M, Ghandi Y, et al. Selenium Supplementation and the Effects on Reproductive Outcomes, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome. Horm Metab Res. 2016;48(3):185-90. doi:10.1055/s-0035-1559604.
28. Jamilian M, Razavi M, Fakhrie Kashan Z, Ghandi Y, Bagherian T, Asemi Z. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2015;82(6):885-91. doi:10.1111/cen.12699.
29. Nasiadek M, Stragierowicz J, Klimczak M, Kilanowicz A. The Role of Zinc in Selected Female Reproductive System Disorders. Nutrients. 2020;12(8):2464. doi:10.3390/nu12082464.
30. Jamilian M, Foroozanfard F, Bahmani F, Talaee R, Monavari M, Asemi Z. Effects of Zinc Supplementation on Endocrine Outcomes in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2016;170(2):271-8. doi:10.1007/s12011-015-0480-7.
31. Foroozanfard F, Jamilian M, Jafari Z, Khassaf A, Hosseini A, Khorammian H, et al. Effects of zinc supplementation on markers of insulin resistance and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Exp Clin Endocrinol Diabetes. 2015;123(4):215-20. doi:10.1055/s-0035-1548790.
32. Mohd Shukri MF, Norhayati MN, Badrin S, Abdul Kadir A. Effects of L-carnitine supplementation for women with polycystic ovary syndrome: a systematic review and meta-analysis. PeerJ. 2022;10:e13992. doi:10.7717/peerj.13992.
33. Samimi M, Jamilian M, Ebrahimi FA, Rahimi M, Tajbakhsh B, Asemi Z. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2016;84(6):851-7. doi:10.1111/cen.13003.
34. Melo V, Silva T, Silva T, Freitas J, Sacramento J, Vazquez M, et al. Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS) - a review of clinical trials and cohort. Endocr Regul. 2022;56(1):66-79. doi:10.2478/enr-2022-0008.
35. Mirmasoumi G, Fazilati M, Foroozanfard F, Vahedpoor Z, Mahmoodi S, Taghizadeh M, et al. The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Exp Clin Endocrinol Diabetes. 2018;126(4):222-8. doi:10.1055/s-0043-119751.
36. Karakas SE, Perroud B, Kind T, Palazoglu M, Fiehn O. Changes in plasma metabolites and glucose homeostasis during omega-3 polyunsaturated fatty acid supplementation in women with polycystic ovary syndrome. BBA Clin. 2016;5:179-85. doi:10.1016/j.bbacli.2016.04.003.
37. Khani B, Mardanian F, Fesharaki SJ. Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. J Res Med Sci. 2017;22:64. doi:10.4103/jrms.JRMS_644_16.
38. Izadi A, Shirazi S, Taghizadeh S, Gargari BP. Independent and Additive Effects of Coenzyme Q10 and Vitamin E on Cardiometabolic Outcomes and Visceral Adiposity in Women With Polycystic Ovary Syndrome. Arch Med Res. 2019;50(1):1-10. doi:10.1016/j.arcmed.2019.04.004.
39. Hariri Z, Yari Z, Hoseini S, Abhari K, Sohrab G. Synbiotic as an ameliorating factor in the health-related quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-controlled trial. BMC Womens Health. 2024;24(1):19. doi:10.1186/s12905-023-02868-1.
40. Xia Y, Wang Y, Cui M, Su D. Efficacy of omega-3 fatty acid supplementation on cardiovascular risk factors in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(6):6425-37. doi:10.21037/apm-21-1050.
41. Yang K, Zeng L, Bao T, Ge J. Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2018;16(1):27. doi:10.1186/s12958-018-0346-x.
42. Liu Z, Tian Z, Zhao D, Liang Y, Dai S, Liu M, et al. Effects of Coenzyme Q10 Supplementation on Lipid Profiles in Adults: A Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2022;108(1):232-49. doi:10.1210/clinem/dgac585.
43. Raizner AE. Coenzyme Q10. Methodist Debakey Cardiovasc J. 2019;15(3):185-91. doi:10.14797/mdcj-15-3-185.
44. Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, et al. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. Int J Endocrinol. 2016;2016:6306410. doi:10.1155/2016/6306410.
45. Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecol Endocrinol. 2019;35(3):198-206. doi:10.1080/09513590.2018.1540578.
46. Razavi M, Jamilian M, Karamali M, Bahmani F, Aghadavod E, Asemi Z. The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Horm Metab Res. 2016;48(6):446-51. doi:10.1055/s-0042-104060.
47. Karamali M, Ashrafi M, Razavi M, Jamilian M, Akbari M, Asemi Z. The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome. Exp Clin Endocrinol Diabetes. 2017;125(5):316-21. doi:10.1055/s-0043-104530.
48. Tarkesh F, Namavar Jahromi B, Hejazi N, Hoseini G. Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial. BMC Womens Health. 2022;22(1):315. doi:10.1186/s12905-022-01825-8.
49. Huang Q, Liu Z, Yang Y, Yang Y, Huang T, Hong Y, et al. Selenium Nanodots (SENDs) as Antioxidants and Antioxidant-Prodrugs to Rescue Islet β Cells in Type 2 Diabetes Mellitus by Restoring Mitophagy and Alleviating Endoplasmic Reticulum Stress. Adv Sci (Weinh). 2023;10(13):e2300880. doi:10.1002/advs.202300880.
50. Li S, Zhao Q, Zhang K, Sun W, Li J, Guo X, et al. Selenium Deficiency-Induced Pancreatic Pathology Is Associated with Oxidative Stress and Energy Metabolism Disequilibrium. Biol Trace Elem Res. 2021;199(1):154-65. doi:10.1007/s12011-020-02140-9.
51. Di Lorenzo C, Ceschi A, Kupferschmidt H, Lüde S, De Souza Nascimento E, Dos Santos A, et al. The variability of nutritional supplement efficacy in clinical studies: A systematic overview. Nutrients. 2020;12(5):1350. doi:10.3390/nu12051350.
52. Vázquez-Lorente H, Molina-López J, Herrera-Quintana L, Gamarra-Morales Y, López-González B, Planells E. Confounding variables in clinical nutrition trials: An under-discussed issue. J Clin Med. 2021;10(1):88. doi:10.3390/jcm10010088.
53. Wang X, Zhang Y, Tan H, Zhao W, Zhao Y, Zheng W. Efficacy of monotherapy vs. co-supplementation in PCOS: A comparative analysis. Endocr Rev. 2019;40(3):517-33. doi:10.1210/er.2018-00238.
54. Ghanei L, Hariri M, Asbaghi O, Kashkooli S, Kashani A, Tavasoli S. Safety concerns and effectiveness of long-term vitamin D and selenium use in endocrine disorders. Clin Endocrinol (Oxf). 2022;97(6):851-60. doi:10.1111/cen.14801.
55. Hussain H, Al-Farhan H, Al-Otaibi S, Al-Massarani S, Al-Rasheed N. Melatonin supplementation in metabolic syndromes: Promises and limitations. Int J Endocrinol. 2023;2023:2548893. doi:10.1155/2023/2548893.
56. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3 (updated 2022). Cochrane; 2022.
57. Palomba S, Piltonen TT, Giudice LC. Nutraceutical approach to PCOS: clinical evidence and future perspectives. Hum Reprod Update. 2023;29(2):187-202. doi:10.1093/humupd/dmac032.
58. Vinceti M, Filippini T, Del Giovane C, Dennert G, Zwahlen M, Brinkman M, et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018;1(1):CD005195. doi:10.1002/14651858.CD005195.pub4.
59. Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE, et al. Selenium in human health and disease. Antioxid Redox Signal. 2011;14(7):1337-83. doi:10.1089/ars.2010.3275.
60. Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res. 2006;21(2):V64-V68. doi:10.1359/jbmr.06s223.
61. Ianiro G, Rossi E, Thomas AM, Schinzari G, Masucci L, Quaranta G, et al. Dietary supplements and drug interactions: a practical guide for clinicians. Eur Rev Med Pharmacol Sci. 2020;24(9):5095-100. doi:10.26355/eurrev_202005_21206.
62. Gurley BJ, Steelman SC, Thomas SL. Adulteration of dietary supplements and the need for improved regulatory oversight. Food Chem Toxicol. 2020;140:111346. doi:10.1016/j.fct.2020.111346.
63. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Genetics of PCOS and its implication for diagnosis and treatment. Best Pract Res Clin Endocrinol Metab. 2011;25(2):139-52. doi:10.1016/j.beem.2010.08.015.
64. Cohen PA. American roulette — contaminated dietary supplements. N Engl J Med. 2014;371(18):1763-6. doi:10.1056/NEJMp1405831.
65. Jamilian M, Foroozanfard F, Mirhosseini N, Bahmani F, Taghizadeh M, Asemi Z. Effects of melatonin supplementation on hormonal, inflammatory, genetic, and oxidative stress parameters in women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2019;10:273. doi:10.3389/fendo.2019.00273
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with BioNatura Journal agree to the following terms: Authors retain copyright and grant the BioNatura Institutional Publishing Consortium (BIPC) right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
